Using a Targeted Proteomics Chip to Explore Pathophysiological Pathways for Incident Diabetes- The Malmö Preventive Project.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 01 2019
22 01 2019
Historique:
received:
22
06
2018
accepted:
21
11
2018
entrez:
24
1
2019
pubmed:
24
1
2019
medline:
7
7
2020
Statut:
epublish
Résumé
Multiplex proteomic platforms provide excellent tools for investigating associations between multiple proteins and disease (e.g., diabetes) with possible prognostic, diagnostic, and therapeutic implications. In this study our aim was to explore novel pathophysiological pathways by examining 92 proteins and their association with incident diabetes in a population-based cohort (146 cases of diabetes versus 880 controls) followed over 8 years. After adjusting for traditional risk factors, we identified seven proteins associated with incident diabetes. Four proteins (Scavenger receptor cysteine rich type 1 protein M130, Fatty acid binding protein 4, Plasminogen activator inhibitor 1 and Insulin-like growth factor-binding protein 2) with a previously established association with incident diabetes and 3 proteins (Cathepsin D, Galectin-4, Paraoxonase type 3) with a novel association with incident diabetes. Galectin-4, with an increased risk of diabetes, and Paraoxonase type 3, with a decreased risk of diabetes, remained significantly associated with incident diabetes after adjusting for plasma glucose, implying a glucose independent association with diabetes.
Identifiants
pubmed: 30670722
doi: 10.1038/s41598-018-36512-y
pii: 10.1038/s41598-018-36512-y
pmc: PMC6342982
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
272Références
Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):542-7
pubmed: 11304470
Eur J Epidemiol. 2001;17(11):983-9
pubmed: 12380709
J Lipid Res. 2005 Jun;46(6):1239-47
pubmed: 15772423
J Cell Biol. 2005 May 9;169(3):491-501
pubmed: 15883199
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791
Lancet. 2006 Nov 11;368(9548):1696-705
pubmed: 17098089
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
Heart Vessels. 2007 May;22(3):158-64
pubmed: 17533519
Diabetes Care. 2008 Oct;31(10):2038-43
pubmed: 18591403
Diabetes Metab Res Rev. 2009 Jan;25(1):3-12
pubmed: 19145587
J Immunol. 2009 Mar 1;182(5):2641-53
pubmed: 19234158
Am Heart J. 2010 Mar;159(3):414-420.e4
pubmed: 20211303
Circulation. 2010 May 18;121(19):2102-8
pubmed: 20439785
Biochimie. 2010 Nov;92(11):1635-43
pubmed: 20493920
Clin Chem. 2011 Feb;57(2):291-7
pubmed: 21106861
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Diabetes. 2012 Sep;61(9):2248-54
pubmed: 22554827
Diabetes Care. 2012 Aug;35(8):1701-7
pubmed: 22584136
Blood. 2012 Dec 6;120(24):4873-81
pubmed: 22990020
Adipocyte. 2013 Jul 1;2(3):170-5
pubmed: 23991364
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
PLoS One. 2014 Nov 13;9(11):e112277
pubmed: 25393737
J Endocrinol Invest. 2015 May;38(5):527-33
pubmed: 25501605
Ann Cardiol Angeiol (Paris). 2016 Apr;65(2):81-6
pubmed: 25813652
Cardiovasc Diabetol. 2015 May 13;14:52
pubmed: 25964115
J Lipid Res. 2015 Sep;56(9):1762-73
pubmed: 26168996
Diabetes. 2016 Jan;65(1):276-84
pubmed: 26420861
Sci Rep. 2016 Jan 27;6:17714
pubmed: 26813008
Lancet. 2016 Apr 9;387(10027):1513-30
pubmed: 27061677
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Can J Diabetes. 2016 Dec;40(6):570-575
pubmed: 27476052
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Sci Rep. 2017 Aug 18;7(1):8707
pubmed: 28821884
J Am Coll Cardiol. 2018 Jan 30;71(4):386-398
pubmed: 29389354
Sci Rep. 2018 Apr 3;8(1):5531
pubmed: 29615742
Nature. 2018 Jun;558(7708):73-79
pubmed: 29875488
JAMA. 1982 May 14;247(18):2543-6
pubmed: 7069920
Science. 1996 Nov 22;274(5291):1377-9
pubmed: 8910278